

Eli Lilly Explores the Latest Advancements in the Pharmaceutical Industry: Interview Released with Lewis Vidler

LONDON, UNITED KINGDOM, January 12, 2017 /EINPresswire.com/ -- In the run up to [Drug Discovery 2017](#), SMI Group has released an interview with leading global pharma manufacturers Eli Lilly.

In a recent interview with Eli Lilly Research Scientist Lewis Vidler, he talked about his perspectives on the current advancements within the field. When asked about recent successful innovations within the drug discovery and development landscape, he said "Being a computational chemist, I am always keen to see new structural biology techniques appear. Recently, Cryo- electron microscopy has seen a boost through the use of direct electron detectors. I hope these techniques can be applied to targets which are not amenable to crystallography or NMR studies to yield greater insight into the structure of different proteins and protein complexes."



Drug Discovery 27-28 March

The full interview is available in the [download centre at the event website](#).

Lewis will be a key speaker at Drug Discovery 2017. Focusing on target identification, he will explore large scale analysis of a pharmaceutical company database to inform future discovery. His presentation will evaluate the Lilly database looking into compounds showing promiscuous or assay-interfering behaviour. He will also discuss approaches involving compound fragmentation and analysis of molecules containing the fragments, as well as identification of fragments enriching for compound promiscuity, instability and cytotoxicity.

In addition to Lewis Vidler, there will be many more [industry leaders](#) who will highlight future opportunities for novel therapeutic discovery including Johnson & Johnson, GSK, AstraZeneca, Novartis, and many more. Attendees will have the chance to join a network of industry innovators and deliberate issues surrounding pre-clinical aspects of drug development, target identification, novel technologies, and access to new chemical matter, protein-based discover, and structural screening.

Drug Discovery will take place on the 27th and 28th of March 2017 at the Holiday Inn Kensington Forum in London.

For more updates on the conference, please visit www.drug-discovery.co.uk/EIN

Drug Discovery
27 & 28 March 2017
Holiday Inn Kensington Forum, London, UK
www.drug-discovery.co.uk/EIN

---end ---

Contact Information:

For sponsorship and exhibition queries please contact Alia Malick at amalick@smi-online.co.uk. For delegate queries please contact Fateja Begum at fbegum@smi-online.co.uk. For media queries please contact Garrett Goolsby at ggoalsby@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Honey de Gracia
SMi Group Ltd
+44 (0)20 7827 6102
[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.